I totally agree with gmcc and perhaps the market will now realise Summits potential also adding that c-diff is funded. I also agree that the long stop position for DMD will be future placements but as currently demonstrated hopefully it may not dilute the share price. Upwards and onwards.
Summit have two outstanding drug assets that have successfully completed with flying colours phase one trials on healthy patients - no reason not to believe one or both will not be extremely successful!
C-Diff SMT19969 should be the first Summit drug to enter market! Possible cash sale could happen anytime if that is the preferred option? Not sure what say if any Wellcome Trust have in the decision process ? ( Summit should make these agreement details public - full transparency ! )
Reminder : SMT19969: C-DIFF peer reviews - drug performance better than existing antibiotics !
“The study also reported that SMT 19969 was highly sparing of gut flora with only the clostridia bacterial family being reduced to levels below the limit of detection. These top-level results provide an encouraging indication of the efficacy and specificity of SMT 19969 in CDI patients.
CEO mentioned deal could be worth £300 million – other recent c-diff sale Optima Pharmaceuticals / Cubist Pharmaceuticals paid $800 million!
Good luck everyone ! ------------ Some links if you care to browse : “Collectively these data suggest that buyers are willing to pay higher than average amounts to access compelling science, especially after it has crossed the threshold into clinical trials.”
"Professor Steve Davies said: "We want to ensure that this utrophin modulation therapeutic approach has the best chance of success in the shortest time for treating Duchenne Muscular Dystrophy. We are delighted to join forces with Summit plc in developing, alongside first in class SMT C1100, these back-up and potentially best in class candidates".
Reminder :SMT C1100 has designated orphan drug status by the US Food & Drug Administration and the European Medicines Agency. Orphan drugs receive a number of benefits including extended market exclusivity following approval and additional regulatory support. In addition, orphan drug products often command premium pricing!
OK " Paramount relationship " required 42.4 million shares -perhaps " lock in period 2 years" gives a clue when SMTC1100 + new compounds ready for production !-maybe earlier with accelerated approval !
Commercial payback from DMD premium pricing far outweighs any perceived share dilution in fact you can expect future placements will be required if a c-diff deal is not struck in 2014 -Summit have stated they need to raise additional funding next year , that’s the reality of being a small R&D biotech operation !
Only ever watched SAR from the sidelines and will continue to hopeful of some news to give me the confidence to invest. That will probably depend on phase 1 design now. I think they were a little premature in their use of the 't' word. Summit also used to have an over excitable board but the new team seem appropritely restrained, although I truely believe 2014/15 will be the time for the correct use of the 't' word at Summit. GLA
Not an unhappy chappy EP! Would be nice to be 100% up, but first dipped my toe in with about 20k5 @12.22 in Aug. Watching ever since! Mondays 100k top-up @ 9.68 gives me an average 10.11 so currently in the right colour. Have absolute confidence in the long term though, that's why I am here.......... :-) By comparison, am heavily into PLE (missed the opportunity for another top-up this morning when sp was well down, but can't sit here at the kb all day!!) MARL, TLDH and TEP also making me smile lately. (even though I sold half my TEP last month to invest elsewhere - still my largest holding!) Thanks and GL to you.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.